Advances in pneumococcal antibiotic resistance

Area of Science:

• Microbiology
• Infectious Diseases
• Vaccinology

Background:

• Antimicrobial resistance and serotypes in Streptococcus pneumoniae are evolving due to antibiotic use and pneumococcal conjugate vaccines (PCV).
• Macrolide resistance has significantly increased globally, exceeding 70% in clinical isolates from Asian countries.
• Changes in resistance breakpoints have decreased penicillin resistance but increased resistance to other beta-lactams like cefuroxime.

Purpose of the Study:

• To analyze the evolving landscape of antimicrobial resistance and serotypes in Streptococcus pneumoniae.
• To assess the impact of pneumococcal conjugate vaccines on drug-resistant strains.
• To highlight the growing concern of multidrug resistance in invasive pneumococcal diseases, especially in Asia.

Main Methods:

• Analysis of antimicrobial resistance patterns and serotype prevalence in Streptococcus pneumoniae isolates.
• Review of trends in resistance breakpoints and vaccine impact.
• Epidemiological assessment of invasive pneumococcal diseases.

Main Results:

• Macrolide resistance is a major concern, with high prevalence in Asian countries.
• Serotype 19A emerged as a significant cause of invasive pneumococcal disease post-PCV7, often linked to multidrug resistance.
• Widespread use of PCV13 may decrease the spread of drug-resistant 19A pneumococci.

Conclusions:

• Multidrug resistance in Streptococcus pneumoniae, particularly in Asian countries, poses a serious threat to treating invasive pneumococcal diseases.
• Pneumococcal conjugate vaccines, especially PCV13, show potential in controlling the spread of drug-resistant serotypes.
• Continued surveillance of antimicrobial resistance and serotype distribution is crucial for effective pneumococcal disease management.